EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Precision oncology in gastric cancer: navigating molecular subtypes, therapeutic targets, and future horizons

Yanyun Hong, Xiaodong Wang, Hang Yu, Xiaosun Liu, Chao Tang

Cellular Oncology · 2026

DOI: 10.1007/s13402-026-01218-1 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cellular Oncology, 2026. Verfasst von Yanyun Hong und 4 weiteren Autor:innen. Beteiligte Einrichtung: Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents' Health and Diseases, No.…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Precision Medicine, Molecular Targeted Therapy, Medical Oncology. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gastric cancer (GC) remains a leading cause of cancer-related mortality globally and is characterized by significant inter- and intra-tumoral heterogeneity, which poses major challenges to effective treatment. Although traditional "one-size-fits-all" chemotherapy regimens have improved outcomes, the prognosis for advanced disease remains poor, necessitating a paradigm shift towards personalized medicine. This review provides a comprehensive synthesis of the current landscape of precision oncology in GC. We systematically analyze the clinical implications of major molecular classification systems, particularly The Cancer Genome Atlas (TCGA) subtypes (EBV-positive, MSI-H, GS, and CIN), and their role in guiding therapeutic stratification. The integration of molecular profiling has revolutionized the management of GC. We discuss the evolution of targeted therapies, ranging from established standards, like HER2 inhibition, to emerging targets, including Claudin18.2 and FGFR2, highlighting their potential of overcoming resistance mechanisms. Furthermore, we evaluate the efficacy of immune checkpoint inhibitors (PD-1/PD-L1 blockade), specifically in the context of high microsatellite instability (MSI-H) and EBV-positive subtypes, where these have demonstrated robust antitumor activity. Beyond tissue-based markers, this article also explores the expanding role of liquid biopsies, including circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), as non-invasive tools for real-time monitoring of disease progression and therapeutic response. Precision oncology represents a transformative approach in GC, moving beyond histology to a molecularly driven treatment framework. However, realizing its full potential requires addressing challenges related to tumor heterogeneity and drug resistance. Future research must focus on validating novel biomarkers and developing synergistic combination strategies to further improve patient survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsPrecision MedicineMolecular Targeted TherapyMedical OncologyHumansBiomarkers, Tumor

Stichwörter der Autor:innen

Gastric cancerImmunotherapyLiquid biopsyMolecular subtypesPrecision oncologyTargeted therapy

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents' Health and Diseases, No.3333, Binsheng Rd, Hangzhou, 310052, China.
  • The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, Zhejiang Province, 310000, China.
  • The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, Zhejiang Province, 310000, China. xiaosunliu@zju.edu.cn.
  • Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents' Health and Diseases, No.3333, Binsheng Rd, Hangzhou, 310052, China. chtang@zju.edu.cn.

Zitieren

APA

Hong, Y., Wang, X., Yu, H., Liu, X., & Tang, C. (2026). Precision oncology in gastric cancer: navigating molecular subtypes, therapeutic targets, and future horizons. Cellular Oncology. https://doi.org/10.1007/s13402-026-01218-1

Vancouver

Hong Y, Wang X, Yu H, Liu X, Tang C. Precision oncology in gastric cancer: navigating molecular subtypes, therapeutic targets, and future horizons. Cellular Oncology. 2026. doi:10.1007/s13402-026-01218-1

BibTeX
@article{Hong2026,
  author = {Hong, Yanyun and Wang, Xiaodong and Yu, Hang and Liu, Xiaosun and Tang, Chao},
  title = {Precision oncology in gastric cancer: navigating molecular subtypes, therapeutic targets, and future horizons},
  journal = {Cellular Oncology},
  year = {2026},
  doi = {10.1007/s13402-026-01218-1}
}
Kostenlos starten →